Medacta Group SA
SIX:MOVE
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| CH |
|
Medacta Group SA
SIX:MOVE
|
3.4B CHF |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
188.5B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
173.6B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
138.1B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
135.7B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
134.2B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
58.9B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
47.1B EUR |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
50.8B USD |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
47.9B USD |
Loading...
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
37B USD |
Loading...
|
Market Distribution
| Min | -13 700% |
| 30th Percentile | 34.9% |
| Median | 49.4% |
| 70th Percentile | 65.3% |
| Max | 137.7% |
Other Profitability Ratios
Medacta Group SA
Glance View
Medacta Group SA, hailing from the picturesque setting of Castel San Pietro, Switzerland, stands as a prominent player in the global medical technology arena. Founded in 1999, the company has capitalized on a family-driven passion for innovation and precision in the orthopedic industry. Guided by its roots, Medacta designs and supplies orthopedic implants and surgical instruments, with a staunch focus on products for joint replacement, spine surgery, and sports medicine. But beyond mere manufacturing, Medacta combines cutting-edge research with in-depth medical training programs, ensuring that healthcare professionals are not only equipped with superior products but also with the necessary skills to optimize patient outcomes. The company’s MyPractice Development Plan exemplifies this by pairing technical support with educational efforts, fostering both confidence and competence among its professional clients. Medacta’s business model is a synthesis of product sales and continuous practitioner engagement. Revenue streams primarily flow from the direct sale of their extensive product portfolio, including implants and surgical instruments, to hospitals and surgical centers. However, Medacta's strategy extends its competitive advantage by nurturing strong relationships with medical professionals through training and support initiatives. This symbiotic approach ensures a feedback loop that not only tailors their offerings to the evolving needs of the marketplace but also solidifies client loyalty. Their innovative and educational initiatives secure a unique position in the market, allowing Medacta to maintain a balance of economic success and industry leadership by focusing on quality, innovation, and education.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Medacta Group SA is 72.8%, which is above its 3-year median of 71.6%.
Over the last 3 years, Medacta Group SA’s Gross Margin has increased from 70.8% to 72.8%. During this period, it reached a low of 67.5% on Jul 30, 2025 and a high of 70.8% on May 30, 2022.